Table 2.
Study measures
| Empagliflozin | Placebo | |||
|---|---|---|---|---|
| Day 0 | Day 4 | Day 0 | Day 4 | |
| Weight, kg | 68.7 (56.2–76.9) | 65.5 (53.3–75.6) | 59.0 (50.2–70.4) | 60.1 (49.2–67.4) |
| P-sodium, mmol/L | 125.5 (122–127) | 134 (132–136) | 126 (123–127) | 133 (129–136) |
| Absolut change p-sodium levels, mmol/L | 10 (5–14) | 7 (3–13) | ||
| Patients achieving normonatremia, n (%) | 18 (42) | 13 (30) | ||
| P-potassium, mmol/L | 4.0 (3.7–4.3) | 4.2 (4.0–4.4) | 4.0 (3.6–4.2) | 4.2 (4.0–4.5) |
| P-glucose, mmol/L | 6.3 (5.3–6.9) | 5.2 (4.8–5.7) | 6.2 (5.3–7.5) | 5.2 (4.8–6.2) |
| P-urea, mmol/L | 4.4 (2.9–5.5) | 4.9 (3.8–6.8) | 3.7 (3.1–5.2) | 4.2 (3.6–5.1) |
| P-uric acid, mmol/L | 214 (139–287) | 185 (134–241) | 181 (131–252) | 207 (154–259) |
| P-osmolality, mosm/kg | 260 (253–268) | 281 (273–285) | 259 (254–268) | 274 (268–281) |
| U-sodium, mmol/L | 68 (54–99) | 81 (57–125) | 71 (62–100) | 81 (52–129) |
| U-glucose, mmol/L | 0.0 (0–0) | 111.2 (56–162) | 0.0 (0–0) | 0.3 (0.2–0.5) |
| U-urea, mmol/L | 127 (81–169) | 180 (121–247) | 125 (84–171) | 159 (100–216) |
| U-uric acid, μmol/L | 1131 (608–2350) | 2126 (1501–2922) | 1277 (637–1932) | 1623 (1158–2719) |
| U-osmolality, mosm/kg | 419 (297–488) | 634 (490–759) | 418 (291–514) | 448 (357–545) |
| FE sodium | 0.97 (0.5–1.51) | 0.64 (0.43–1.34) | 0.79 (0.45–1.26) | 0.67 (0.40–1.19) |
| FE urea | 46.5 (35.4–55.8) | 39.6 (32.7–46.7) | 42.0 (35.9–54.0) | 41.8 (30.6–50.0) |
| FE uric acid | 11.2 (8.8–14.8) | 12.9 (9.2–18.2) | 10.9 (5.9–13.9) | 9.7 (8.0–12.6) |
Summary statistics of study measures according to the full analysis set. Categorical variables are shown as frequencies (percentage), and numerical variables are shown as median (IQR). P, plasma; U, urinary; FE, fractional excretion.